Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations

Fig. 2

Cumulative incidence of brain metastasis progression using competing risks regression analysis in patients treated with gefitinib or erlotinib. a All patients in this study. b Patients who had brain metastasis before EGFR-TKI administration. c Patients who had no brain metastasis before EGFR-TKI administration

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us